OBEXELIMAB

UNII:	RM16A4BA8R
Formula:
Preferred Substance Name:	OBEXELIMAB

1690307-05-1
IMMUNOGLOBULIN G1, ANTI-(HUMAN CD19 ANTIGEN) (HUMAN-MUS MUSCULUS MONOCLONAL XMAB5871 HEAVY CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL XMAB5871 LIGHT CHAIN, DIMER
IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS B-LYMPHOCYTE ANTIGEN CD19 (DIFFERENTIATION ANTIGEN CD19T-CELL SURFACE ANTIGEN LEU-12))HUMANIZED MOUSE MONOCLONAL ANTIBODY.GAMMA.1 HEAVY CHAIN (1-451) (MUS MUSCULUS VH (IGHV1-14*01 (78%) (IGHD)-IGHJ4*01 (100%)) (8.8.14) (1-121) -HOMO SAPIENS IGHG1*03 (CH1(R120>K(218)), CH2(S29>E(271),L113>F(332)) (122-451)) (224-219')-DISULFIDE WITH .KAPPA. LIGHT CHAIN (1'-219') (MUS MUSCULUS V-KAPPA (IGKV2-137*01 (75%) IGKJ2*03 (91%))(11.3.9) (1'-112') -HOMO SAPIENS IGKC*01 (113'-219')), DIMER (230-230'':233-233'')-BISDISULFIDE
OBEXELIMAB [INN]
OBEXELIMAB [USAN]
OBEXELIMAB [WHO-DD]
XMAB5871
XMAB-5871
XMAB5871 (HUMANIZED ANTI-CD19 ANTIBODY WITH AN FC PORTION ENGINEERED FOR INCREASED AFFINITY (200- TO 400-FOLD OVER NATIVE IGG) TO FCGRIIB)

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.

OBEXELIMAB

Synonyms and Mappings

Resources